

(51) International Patent Classification:
C07K 16/28 (2006.01) C07K 16/30 (2006.01)(21) International Application Number:
PCT/US2019/025032(22) International Filing Date:
29 March 2019 (29.03.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/650,955 30 March 2018 (30.03.2018) US(71) Applicant: EUREKA THERAPEUTICS, INC. [US/US];
5858 Horton Street, Suite 370, Emeryville, California 94608 (US).

(72) Inventors; and

(71) Applicants: CUI, Jun [CN/US]; c/o Eureka Therapeutics, Inc., 5858 Horton Street, Suite 370, Emeryville, California 94608 (US). ZHANG, Pengbo [CN/US]; c/o Eureka Therapeutics, Inc., 5858 Horton Street, Suite 370, Emeryville, California 94608 (US). XU, Yiyang [US/US]; c/o Eureka Therapeutics, Inc., 5858 Horton Street, Suite 370, Emeryville, California 94608 (US). LI, Shan [CN/US]; c/o Eureka Therapeutics, Inc., 5858 Horton Street, Suite 370, Emeryville, California 94608 (US). XU, Yixiang [CN/US]; c/o Eureka Therapeutics, Inc., 5858 Horton Street, Suite 370, Emeryville, California 94608 (US). XIONG, Guangyan [CN/US]; c/o Eureka Therapeutics,

Inc., 5858 Horton Street, Suite 370, Emeryville, California 94608 (US).


(72) Inventors: YUN, Hongruo; c/o Eureka Therapeutics, Inc., 5858 Horton Street, Suite 370, Emeryville, California 94608 (US). LIU, Lianxing; c/o Eureka Therapeutics, Inc., 5858 Horton Street, Suite 370, Emeryville, California 94608 (US). GE, Xiaomei; c/o Eureka Therapeutics, Inc., 5858 Horton Street, Suite 370, Emeryville, California 94608 (US). XU, Shaohua; c/o Eureka Therapeutics, Inc., 5858 Horton Street, Suite 370, Emeryville, California 94608 (US). LIU, Hong; c/o Eureka Therapeutics, Inc., 5858 Horton Street, Suite 370, Emeryville, California 94608 (US). MORALES, Javier; c/o Eureka Therapeutics, Inc., 5858 Horton Street, Suite 370, Emeryville, California 94608 (US).

(74) Agent: YAO, Zhengzheng et al.; Kilpatrick Townsend & Stockton LLP, Mailstop: IP Docketing - 22, 1100 Peachtree Street, Suite 2800, Atlanta, Georgia 30309 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

(54) Title: CONSTRUCTS TARGETING CD22 AND USES THEREOF

(57) Abstract: Described herein are antibodies (e.g., single chain variable fragment (scFv) antibodies) and constructs comprising antibody moieties that bind to the extracellular domain of CD22 or a portion thereof (e.g., SEQ ID NO:205 or a portion thereof). Also provided herein are methods of using the same or compositions thereof for the therapeutic treatment of diseases characterized by CD22 expression, in particular, B-cell lymphomas and leukemias.

FIG. 1A
Jurkat

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*